NIMble innovation-a networked model for public antibiotic trials

Area of Science:

• Pharmaceutical Sciences
• Public Health
• Drug Development

Background:

• Antibiotic innovation faces significant commercialization challenges, hindering the development of new life-saving drugs.
• Existing research and development (R&D) initiatives require better coordination and sustainable funding to progress promising compounds.
• The pipeline for new antibiotics is insufficient to combat the growing threat of antimicrobial resistance.

Purpose of the Study:

• To propose a Networked Institute Model for public antibiotic R&D.
• To outline a global public infrastructure for advancing antibiotic compounds through clinical trials.
• To ensure sustainable drug production and equitable access through innovative funding and distribution mechanisms.

Main Methods:

• Establishment of a global public infrastructure comprising specialized institutes.
• Conducting all clinical trial stages from early research to market authorization.
• Managing small-scale compound production and negotiating industry licensing agreements.
• Implementing public purchasing or subscription models for viable and equitable drug pricing.

Main Results:

• The proposed model facilitates the progression of antibiotic candidates through the entire drug development pipeline.
• It establishes a framework for coordinating public and private R&D efforts.
• It ensures sustainable commercial viability and equitable global access to essential antibiotics.

Conclusions:

• The Networked Institute Model offers a viable solution to unblock the antibiotic R&D pipeline.
• This public-private partnership approach can overcome commercialization barriers.
• Implementing this model is crucial for addressing the global health crisis of antimicrobial resistance.